RANTES activates antigen-specific cytotoxic T lymphocytes in a mitogen-like manner through cell surface aggregation.

RANTES (regulated upon activation, normal T cell expressed and secreted) is released by cytotoxic T lymphocytes (CTL), and is a potent chemoattractant factor for monocytes and T cells, also known for its ability to suppress HIV infection. At micromolar concentration, RANTES is able to activate leukocytes, and, paradoxically, to enhance HIV infection in vitro. These latter properties are dependent on its ability to self-aggregate. In order to understand further the mechanism of RANTES-induced activation, the effects of both aggregated and disaggregated RANTES on antigen-specific CD8(+) clones were studied in comparison with the effects of specific antigens and in the presence of specific inhibitors of RANTES-mediated activation. We observed large amounts of RANTES aggregated on the cell surface, which led to cell activation, including up-regulation of cell surface markers, and secretion of IFN-gamma and macrophage inflammatory protein (MIP)-1beta. Specific inhibitors of RANTES-induced activation, such as soluble glycosaminoglycans, MIP-1alpha and MIP-1beta, acted by preventing the binding of RANTES on the cell surface. These studies suggest that RANTES acted more like a mitogen than an antigen-independent activator.

[1]  P. W. Janes,et al.  The role of lipid rafts in T cell antigen receptor (TCR) signalling. , 2000, Seminars in immunology.

[2]  V. Appay,et al.  Aggregation of RANTES Is Responsible for Its Inflammatory Properties , 1999, The Journal of Biological Chemistry.

[3]  A. Trkola,et al.  The CC-Chemokine RANTES Increases the Attachment of Human Immunodeficiency Virus Type 1 to Target Cells via Glycosaminoglycans and Also Activates a Signal Transduction Pathway That Enhances Viral Infectivity , 1999, Journal of Virology.

[4]  L. Mollet,et al.  Cutting edge: RANTES regulates Fas ligand expression and killing by HIV-specific CD8 cytotoxic T cells. , 1999, Journal of immunology.

[5]  G. Ogg,et al.  Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. , 1999, Journal of immunology.

[6]  V. Appay,et al.  Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants. , 1999, The Journal of biological chemistry.

[7]  A. Trkola,et al.  Enhancement of Human Immunodeficiency Virus Type 1 Infection by the CC-Chemokine RANTES Is Independent of the Mechanism of Virus-Cell Fusion , 1999, Journal of Virology.

[8]  R. Gallo,et al.  A New Monoclonal Antibody, mAb 4A12, Identifies a Role for the Glycosaminoglycan (GAG) Binding Domain of RANTES in the Antiviral Effect against HIV-1 and Intracellular Ca2+ Signaling , 1998, The Journal of experimental medicine.

[9]  A. Chalian,et al.  CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. , 1998, The Journal of clinical investigation.

[10]  B. Autran,et al.  HIV-specific T Cell Cytotoxicity Mediated by RANTES Via the Chemokine Receptor CCR3 , 1998, The Journal of experimental medicine.

[11]  J. Westwick,et al.  Chemokines: understanding their role in T-lymphocyte biology. , 1998, The Biochemical journal.

[12]  M A Nowak,et al.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. , 1998, Science.

[13]  G. Ogg,et al.  Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood , 1998, Current Biology.

[14]  S. Rowland-Jones,et al.  Antigen–specific release of β-chemokines by anti-HIV-1 cytotoxic T lymphocytes , 1998, Current Biology.

[15]  B. Walker,et al.  β-Chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans , 1998, Nature.

[16]  B. Premack,et al.  RANTES-induced T cell activation correlates with CD3 expression. , 1998, Journal of immunology.

[17]  C. Power,et al.  Glycosaminoglycans mediate cell surface oligomerization of chemokines. , 1997, Biochemistry.

[18]  T. Schall,et al.  RANTES stimulation of T lymphocyte adhesion and activation: role for LFA‐1 and ICAM‐3 , 1997, European journal of immunology.

[19]  茂人 小林,et al.  HLA class I抗原と疾患 , 1996 .

[20]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[21]  T. Schall,et al.  RANTES induces tyrosine kinase activity of stably complexed p125FAK and ZAP-70 in human T cells , 1996, The Journal of experimental medicine.

[22]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[23]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[24]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[25]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[26]  B. Walker,et al.  HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. , 1995, The Journal of clinical investigation.

[27]  B. Premack,et al.  Activation of dual T cell signaling pathways by the chemokine RANTES. , 1995, Science.

[28]  F. Chisari,et al.  Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. , 1995, The Journal of clinical investigation.

[29]  A. Lander,et al.  Differential binding of chemokines to glycosaminoglycan subpopulations , 1994, Current Biology.

[30]  T. Schall.  Biology of the RANTES/SIS cytokine family. , 1991, Cytokine.

[31]  A. McMichael,et al.  Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2 , 1987, Nature.

[32]  C. Hébert.  Chemokines in Disease , 1999, Contemporary Immunology.

[33]  H. Orr,et al.  HLA Class I , 1998 .